Ptc Therapeutics (PTCT) Cash & Current Investments (2012 - 2026)

Ptc Therapeutics' Cash & Current Investments history runs 15 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 6.65% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $1.9 billion (down 6.65% YoY), while the FY2025 annual figure was $1.9 billion, up 70.69% from the prior year.
• Cash & Current Investments was $1.9 billion for Q1 2026 at Ptc Therapeutics, down from $1.9 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.0 billion in Q1 2025 to a low of $286.3 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $1.0 billion across 5 years, with a median of $884.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments slumped 66.77% in 2022, then surged 243.73% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $410.7 million in 2022, then surged by 113.47% to $876.7 million in 2023, then gained by 29.99% to $1.1 billion in 2024, then jumped by 70.69% to $1.9 billion in 2025, then fell by 2.72% to $1.9 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.9 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.